Endoscopically-assisted in-situ lower limb arterial reconstruction is safe and effective: A retrospective cohort study Authors: Sarah Klapman, Aidan M Kirkham, Johann Licht, Michael Yacob Published: 2026 ABSTRACT AbstractObjectiveCompared with the traditional open approach, minimally invasive vascular surgery techniques may offer benefits to patients undergoing lower-extremity arterial reconstruction. We sought to determine whether endoscopically-assisted in-situ lower-extremity bypass for chronic limb-threatening ischemia is as safe and effective as traditional approaches.MethodsFrom 2021 to 2024, we performed a retrospective cohort study of endoscopically-assisted femoropopliteal or femorotibial bypass on 10 patients in an academic hospital in Ontario, Canada. Patients were selected based on the presence of Rutherford grade 4 to 6 ischemia and anatomic suitability for in-situ bypass, aged over 18 years, and ability to tolerate surgery; no patients withdrew from the study but one died of unrelated causes before reaching the 1-year mark after surgery. We recorded patient demographics such as medical comorbidities (such as diabetes and coronary artery disease). We also documented outcomes (such as 1-year amputation-free survival, major adverse cardiac or limb events, and major revascularization). Follow-up with arterial duplex scanning was performed at 1 and 3 months, and then yearly after surgery; data were collected up to 1 year after surgery.ResultsThe mean age of patients was 72.4 years, with 70% males. The amputation-free survival at 1-year was 80%. The 30-day mortality was 0.0%, whereas the 1-year mortality was 10.0%, with the only mortality being secondary to a new diagnosis of gastric cancer. At 1-year follow-up, the primary, primary-assisted, and secondary patency rates were 66.7%, 88.9%, and 100%, respectively. There were no major adverse cardiac events at 30-day or 1-year. No postoperative bleeding events requiring intervention or residual arteriovenous fistulas were identified on surveillance imaging. The median hospitalization length of stay was 4.4 days (1-11).ConclusionsOur outcomes suggest that endoscopically-assisted lower-extremity bypass for chronic limb-threatening ischemia is safe and effective in a select patient population with chronic limb-threatening ischemia.Keywords: Vascular grafting, Vascular surgical procedures, Peripheral vascular diseases Article Highlights •Type of Research: Single-center retrospective cohort study Type of Research: Single-center retrospective cohort study •Key Findings: A new approach to endoscopically-assisted lower-extremity bypass for chronic limb-threatening ischemia in 10 patients resulted in no mortality, 0% 30-day major adverse limb events and major adverse cardiac events, and 88.9% primary-assisted patency at 1 year, which is comparable to traditional in-situ bypass outcome rates in the literature. Key Findings: A new approach to endoscopically-assisted lower-extremity bypass for chronic limb-threatening ischemia in 10 patients resulted in no mortality, 0% 30-day major adverse limb events and major adverse cardiac events, and 88.9% primary-assisted patency at 1 year, which is comparable to traditional in-situ bypass outcome rates in the literature. •Take Home Message: Endoscopically-assisted bypass is a safe and effective option for lower-extremity bypass in chronic limb-threatening ischemia. Take Home Message: Endoscopically-assisted bypass is a safe and effective option for lower-extremity bypass in chronic limb-threatening ischemia. Autologous greater saphenous veins (GSV) provide excellent clinical results in distal arterial bypass grafting for chronic limb-threatening ischemia (CLTI).1 In 2001, Suggs et al2 outlined an endoscopically-assisted approach to GSV harvesting that decreased postoperative complications such as wound infection, dehiscence, arteriovenous fistula, and graft failure. It is worth distinguishing endoscopic vein harvest (EVH) from endoscopically-assisted in-situ bypass (E-SITU), where the former results in full ex-situ vein harvest out of the tissue bed (and subsequent grafting elsewhere), whereas the latter uses the endoscope to assist in branch management, and leaves the vein in-situ. Apart from the previously aforementioned by Suggs et al2 trial, there is very little data to support the safety and efficacy of the E-SITU technique. There is conflicting evidence in the literature about the efficacy of EVH, especially pertaining to decreased primary patency rates compared with traditional open vein harvest (OVH).3, 4, 5 However, a recent study found that EVH reduces complications without compromising graft patency and reintervention rates as compared with OVH.6 As specialist continue to familiarize themselves with the use of the endoscope technology in vein harvest, we are seeing improved outcomes for this manner of conduit management. To that end, in 2024, Michels, Baghdadwala, and Yacob7 published a detailed approach to the E-SITU using modern technologies. We used this approach in an academic hospital in Ontario, Canada from 2021 to 2024 to collect a robust set of updated data on patient outcomes in E-SITU bypass. We hypothesized that, in an experienced center with EVH for cardiac surgery purposes, we could perform E-SITU bypass in patients with CLTI while maintaining outcomes (including amputation-free survival at 1 year, 30-day mortality, incisional complication rate, and 1-year primary patency) which approach the existing data on the standard in-situ bypass. Methods Patients Ten patients requiring femoropopliteal or femorotibial bypass surgery were selected for E-SITU bypass between May 2021 and June 2024. Participant characteristics are listed in Table I. Inclusion criteria were Rutherford grade 4 to 6 ischemia and anatomical suitability for in-situ bypass (significant infrainguinal arterial occlusive disease with subsequent CLTI, appropriate inflow and outflow vessels for harvesting and anastomosis, proximal GSV of at least 2 mm, saphenofemoral junction within 10 mm of the arterial inflow vessel, at least 5 mm of adipose tissue between skin and GSV). Exclusion criteria were aged under 18 years, inability to tolerate general anesthetic, previous vascular reconstruction on the ipsilateral leg, GSV <2 mm, Saphenofemoral junction located >10 mm from patent inflow vessel, less than 5 mm adipose thickness anywhere along the course of the GSV. Patient characteristics are described in Table I. Table IPatient characteristicsCharacteristics (N = 10)Gender Female3 (30.0) Male7 (70.0)Average age, median (range)72.4 (65-82)Coronary artery disease3 (30.0)Earlier coronary artery bypass grafting0 (0.0)Cardiovascular disease8 (80.0)Diabetes6 (60.0)Chronic obstructive pulmonary disease4 (40.0)Earlier congestive heart failure0 (0.0)End-stage renal disease1 (10.0)Active smoking (at time of surgery)6 (60.0)Categorical data are shown as number (%). Patient characteristics Categorical data are shown as number (%). Procedure Patients underwent an E-SITU bypass in the vascular surgery hybrid operating theater, as previously described.7 Additional instrumentation required included an endoscopic retractor, endoscopic camera, laparoscopic diathermy for blunt dissection and thermal division of soft tissues, endoscopic clip applier, and catheter valvulotome. The room setup required a surgeon, surgical assistant, and an additional surgical assistant to operate the endoscopic machinery.7 Patients received preoperative antibiotic prophylaxis [generally cephazolin 2 g intravenously (IV)] within an hour of the operation start time. All patients were placed under general anesthetic. Vessel mapping of the GSV, femoral artery, and saphenofemoral junction were performed using ultrasound guidance. Proximal and distal incisions were made at the anticipated anastomotic sites at the common femoral artery and respective outflow artery, where the GSV was locally dissected out. The endoscopic retractor, endoscope, and diathermy device were inserted, and the GSV tunnel was created using blunt dissection. GSV branches were double clipped without division. The patient was heparinized. If surgical reconstruction of inflow vessels was necessary, this would be performed first. The GSV was divided at the saphenofemoral junction, and spatulated to match an obliqued femoral arteriotomy. The femoral anastomosis was performed in an end-to-side fashion. The distal GSV was divided, and valvulotome passed through at least twice. Any side wall iatrogenic injuries were repaired under direct vision using a figure-of-eight 7-0 prolene. The distal anastomosis was performed in an end-to-side fashion to the outflow artery. In all cases, angiogram was performed via the common femoral artery to assess for remnant fistulas. Any remnant fistulas were then marked; the endoscope was reinserted, advanced, and the fistula was ligated using double clipping without division. The heparin was reversed, and incisions were closed with Vicryl. Monocryl or staples were used to approximate skin. Ankle-brachial index (ABI) was performed before discharge. Surveillance Upon completion of the procedure, participants were entered into our institution's standard surveillance protocol for patients after lower extremity revascularization. Per the Society for Vascular Surgery guidelines, surveillance was initiated with a clinic visit 2 weeks after discharge, followed by arterial duplexes at 1 (clinic visit), 3, and 6 months, and then yearly (all by phone visit).8 Patients would be booked for the next available in-person clinic if they contacted the practice endorsing recurrence of initial symptoms, new claudication, or new critical limb ischemia symptoms. Patients were risk stratified for bypass graft by duplex criteria.9 Patients in Category 1 [highest risk; peak systolic velocity (PSV) > 300 cm/sec; velocity ratio of > 3.5; graft flow velocity < 45 cm/sec; and ABI change > 0.15] or Category 2 (high risk; PSV > 300 cm/sec; velocity ratio of > 3.5; graft flow velocity > 45 cm/sec; and ABI change < 0.15) underwent angioplasty. Patients in Category 3 (moderate risk; PSV 180-300 cm/sec; velocity ratio > 2.0; graft flow velocity > 45 cm/sec; and ABI change <0.15), or Category 4 (low risk; PSV < 80 cm/sec; velocity ratio < 2.0; graft flow velocity > 45 cm/sec; and ABI change < 0.15) were continued on the surveillance protocol. Patients were contacted if concerning findings were identified on duplex to arrange for angiographic interrogation of the bypass. Outcome measures Our primary outcome of interest was amputation-free survival at 1-year (time to above-ankle amputation of the trial leg or death from any cause, whichever came first). Our secondary outcomes included: (1) 30-day mortality and 1-year mortality; (2) 30-day incisional complications (defined as any complication requiring antibiotics); (3) length of hospitalization (in days); (4) 30-day and 1-year major adverse cardiac events (MACE—myocardial infarction, angina, stroke, chronic limb ischemia or above-ankle amputation of the nontrial leg); (5) 30-day and 1-year major adverse limb events (MALE—above-ankle amputation or major additional revascularization of the trial leg)10; (6) 1-year primary patency rate (defined as time from procedure to first additional intervention); (7) 1-year primary-assisted patency rate (defined as time to bypass patency with an additional intervention but without occlusion of the original site); and (8) 1-year secondary patency rate (defined as time to patency of the bypass after additional intervention once occlusion has occurred).11 Major revascularization included new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis.12,13 Data were summarized using medians and ranges, means, and standard deviations, or counts and percentages where appropriate. The 95% confidence interval for all percentages was calculated using the Clopper-Pearson exact binomial method.14 All analyses were preformed using Stata MP V.13.1 (Stata Corporation). Institutional Review Board was not required. Results Patient and procedure characteristics The study cohort consisted of 10 patients with a median age of 72.4 years (range, 65-82 years). The majority of the participants were male (70.0%). High rates of cardiovascular comorbidity were observed, with 80.0% of patients having established cardiovascular disease and 30.0% having coronary artery disease. In addition, 60.0% of the cohort had diabetes; 40.0% had chronic obstructive pulmonary disease; and 10.0% had end-stage renal disease. At the time of surgery, 60.0% of patients were active smokers. Other demographic characteristics are described in Table I. A total of 10 bypass procedures were performed, including four above-knee popliteal, four below-knee popliteal, and two posterior tibial artery bypasses. Concurrent vascular reconstructions were required in 60% of cases, most commonly involving femoral endarterectomy and patch arterioplasty. Two patients (20%) required intraoperative revisions due to iatrogenic injuries, specifically a vein transection and a branch injury requiring additional incision for repair. All procedure characteristics are described in Table II. Table IIProcedure details by patientPatient No.ProceduresConcurrent vascular reconstruction1Right femoral to above-knee popliteal artery in-situ bypass with angiogramNone2Right femoral to below-knee popliteal artery in-situ bypass with angiogramRight common femoral artery endarterectomy3Right femoral to below-knee popliteal artery in-situ bypass with angiogramRight femoral endarterectomy and extended profundoplasty with bovine patch arterioplasty4Right femoral to posterior tibial artery bypass with spliced vein and angiogramGSV iatrogenically transected and repaired with venovenous anastomosis from the distal thigh5Left femoral to above-knee popliteal in-situ bypass with angiogramLeft femoral endarterectomy and bovine patch arterioplasty6Right femoral to above-knee popliteal artery in-situ bypass with angiogramNone7Left femoral to below-knee popliteal in-situ bypass with angiogramMidthigh incision required to fix iatrogenic branch injury8Right femoral to posterior tibial artery bypass with angiogramNone9Left femoral to below-knee popliteal in-situ bypass with angiogramNone10Left femoral to below-knee popliteal artery in-situ bypass with angiogramBalloon angioplasty of anterior tibial artery (beyond distal anastomosis)GSV, Greater saphenous veins. Procedure details by patient GSV, Greater saphenous veins. Patient outcomes Two patients had iatrogenic injuries, including a partial transection of the GSV, and a branch transection. Three patients (30.0%) experienced incisional complications within 30-days, all of which were superficial surgical site infections treated with a single course of oral antibiotics. The amputation free survival at 1-year was 80% (n = 8/10 patients). Only 1 of 10 patients required a same-leg amputation; in this case, an above-knee amputation occurred 32 days after their operation (1-year ipsilateral leg amputation = 10.0%). There was one death within 1-year year of surgery from gastric cancer (1-year mortality = 10.0%), but none related to the surgery itself. At 1-year follow-up, the primary, primary-assisted, and secondary patency rates were 66.7%, 88.9%, and 100%, respectively. During the study period, no patients experienced a deep vein thrombosis, postoperative bleed event requiring reintervention, or residual arteriovenous fistula. All outcomes are described in Table III. Table IIIPatient outcomesOutcomesFrequency (%)Primary outcome Amputation-free survival at 1 year8/10 (80.0)Secondary outcomes Amputation of ipsilateral leg at 30 days0/10 (0.0) Amputation of ipsilateral leg at 1 year1/10 (10.0) 30-day mortality0/10 (0.0) 1-year mortality1/10 (10.0) 30-day incisional complications3/10 (30.0) MACE (30 day)0/10 (0.0) MACE (1 year)0/9a (0.0) Postoperative stroke (30 day)0/10 (0.0) Primary patency rate (1 year)6/9 (66.7) Primary-assisted patency rate (1 year)8/9 (88.9) Secondary patency rate (1 year)9/9 (100) MALE (30 day)0/10 (0.0) MALE (1 year)1/9 (11.1) DVT0/10 (0.0) Postoperative bleeding requiring intervention0/10 (0.0) Median procedure length, minutes (range)214.3 (155-284) Median hospitalization length, days (range)4.4 (1-11) Residual arteriovenous fistula0/10 (0.0)DVT, Deep vein thrombosis; MACE, major adverse cardiac events; MALE, major adverse limb event.Categorical data are shown as number (%).aOwing to early death of one patient, the long-term data is based on nine patients. Patient outcomes DVT, Deep vein thrombosis; MACE, major adverse cardiac events; MALE, major adverse limb event. Categorical data are shown as number (%). Owing to early death of one patient, the long-term data is based on nine patients. Discussion The purpose of this study was to determine whether E-SITU in lower-extremity bypass for CLTI is safe and effective. We collected data on 10 patients who underwent femoropopliteal or femorotibial bypass using E-SITU, including demographic information and outcomes on a 1-year surveillance protocol. Two patients experienced iatrogenic injuries resulting from the surgical procedure, including partial graft transection, and branch avulsion; both repaired using a running 7-0 prolene. Neither patient required revision surgery during the study period. Three patients experienced superficial surgical site infections within 30 days, each treated with a single course of oral antibiotics. At 1-year follow-up, 8 of the 10 patients in our study were alive and free from amputation, one patient required a same-leg amputation within 32 days of surgery, whereas there was one death within 1-year of surgery that was unrelated to the surgical procedure itself. The primary, primary-assisted, and secondary patency rates at 1-year were 66.7%, 88.9%, and 100%, respectively. The frequency of 30-day MALE in our study was 0%. This is similar to previous studies, with 30-days MALE frequencies ranging from 0% to 5%.15 The frequency of 30-day MACE in our study was also 0%. This is also consistent with earlier literature, with 30-day MACE frequencies ranging from 4.1% to 7.8%.16 Nevertheless, our definitions for MACE and MALE were broader than those used within older studies, which have typically focused exclusively on myocardial infarctions.15 The frequency of 30-day incisional complications in our study was 30%. In one case, the patient had a pre-existing groin infection that was ultimately managed postoperatively by our hospital's Infectious Disease team as intertrigo. In another case, antibiotics were prescribed as a precaution based on patient concerns expressed via telecommunication without opportunity for physical assessment of the incision. Notably, the frequency of incisional complications observed in our study is higher than previous studies, in which the frequency of incisional complications ranges from 5% to 7%.17,18 This is likely due to our smaller sample size. None of the infections resulted in reoperation or loss of bypass. The 1-year primary patency observed in our study was 66.7%, whereas the 1-year primary-assisted patency in our study was 88.9%. This is likely evidence of a robust ultrasound screening protocol consistent with best practices.9,13 Our results are also consistent with previous work done by Suggs et al2 on endoscopic-in-situ bypass in the early 2000s. Their 2001 Randomized Controlled Trial reported 1-year primary-assisted patency rate of 91% (endoscopic bypass) and 92% (OVH). The postoperative MACE frequency of 4% for patients undergoing endoscopic procedures, and 8% for patients undergoing open bypasses. Finally, our average length of hospital stay was 4.4 days. This is even lower than previous studies, which have reported length of hospital stays of 6.2 days for endoscopic-in-situ bypass vs 9.2 days for OVH. Therefore, our result provides further support that E-SITU is safe, associated with acceptable patency at 1-year follow-up, and may reduce the length of patient hospital stay when compared with OVH. Our study is limited by the small sample size of 10 pilot patients and the lack of a comparison group. Furthermore, only one surgeon performed all 10 operations, lending to a possibility of expert bias. Furthermore, our center is quite adept at endoscopic management of the GSV as this is standard practice for our institution's cardiac surgery group, we, therefore, benefitted from the experienced support personnel. Our future direction will be to expand the sample size as we perform additional EVH lower limb bypasses, match patients with controls, and collect follow-up data at the 2- and 5-year marks. Conclusions Our results suggest that E-SITU is a reasonable and safe alternative to standard in-situ bypass, in the correct patient population. We observed shorter lengths of stay hospital stay and lower frequencies of mortality, MACE, and MALE compared with previously published data. We also had similar primary, primary assisted, and secondary patency rate to those reported in previously published studies. Although the frequency of incisional complications was slightly higher in our study compared with previous literature, this is likely the result of the small sample size of the study. Future wok is needed to determine which patients may benefit most from this procedure, such as surgically challenging patients, and those with a large body habitus otherwise fit for OVH. Funding No funding was provided. Disclosures The authors have no competing interests. From the Canadian Society for Vascular Surgery Footnotes The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest. References